22:24 , Dec 13, 2018 |  BC Extra  |  Company News

Management tracks: Ambys, Foghorn

Liver regenerative medicine company Ambys Medicines (Redwood City, Calif.) hired Jeff Jonker as president, CEO and a director. He succeeds Interim CEO Jeffrey Tong, who will become chairman. Jonker was president of NGM Biopharmaceuticals Inc....
18:37 , Dec 13, 2018 |  BC Extra  |  Financial News

Biohaven nets $125M ahead of NDA submissions

Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHNV) raised $125 million late Wednesday through the sale of 3.3 million shares at $37.25 in an upsized follow-on. Following positive Phase III data reported this month for rimegepant for...
00:00 , Dec 12, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Neurology Patient sample and mouse studies suggest depleting microglia with CSF1R inhibitors could help treat chemotherapy-induced neurological dysfunction. In postmortem frontal lobe tissue samples from pediatric and young adult patients treated with methotrexate and...
03:14 , Dec 8, 2018 |  BioCentury  |  Regulation

Path to opioid-free pain relief

To jump-start development of analgesics that can help stem the opioid crisis, companies want FDA’s upcoming guidelines to reduce uncertainty around outcomes that constitute clinically meaningful opioid sparing. But while an advisory panel put some...
19:07 , Dec 7, 2018 |  BC Week In Review  |  Financial News

After Ally Bridge-backed series A, Shanghai's GenFleet looks to clinic

With eight preclinical candidates and an experienced management team, immunology company GenFleet Therapeutics Co. Ltd. (Shanghai, China) raised RMB120 million ($17.4 million) in an untranched series A round to bring its first therapy into clinic...
17:58 , Dec 7, 2018 |  BC Week In Review  |  Clinical News

Biohaven's orally dissolving tablet meets in Phase III for acute migraine

Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) said its orally dissolving tablet (ODT) formulation of rimegepant met the co-primary endpoints in the Phase III BHV3000-303 trial for the acute treatment of migraine. The company updated its...
16:24 , Dec 7, 2018 |  BC Extra  |  Clinical News

Imfinzi-tremelimumab combo fails Phase III for head and neck cancer

In yet another setback for tremelimumab, AstraZeneca plc (LSE:AZN; NYSE:AZN) said the anti-CTLA-4 mAb in combination with PD-L1 inhibitor Imfinzi durvalumab missed the primary endpoint of improving overall survival (OS) compared with standard of care...
01:28 , Dec 7, 2018 |  BC Week In Review  |  Clinical News

AbbVie's Rova-T suffers another setback in SCLC

AbbVie Inc. (NYSE:ABBV) said on Dec. 5 that it will stop enrollment in the Phase III TAHOE trial of Rova-T rovalpituzumab tesirine as second-line treatment of advanced or metastatic small cell lung cancer after the...
23:31 , Dec 6, 2018 |  BC Extra  |  Financial News

After Ally Bridge-backed series A, Shanghai's GenFleet looks to clinic

With eight preclinical candidates and an experienced management team, immunology company GenFleet Therapeutics Co. Ltd. (Shanghai, China) raised RMB120 million ($17.4 million) in an untranched series A round to bring its first therapy into clinic...
23:42 , Dec 5, 2018 |  BC Extra  |  Clinical News

AbbVie's Rova-T suffers another setback in SCLC

AbbVie Inc. (NYSE:ABBV) said late Wednesday that it will stop enrollment in the Phase III TAHOE trial of Rova-T rovalpituzumab tesirine as second-line treatment of advanced or metastatic small cell lung cancer after the product...